

## Gambia Support for Meningitis A Preventive Routine Support

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Gambia						
<b>2. Grant number:</b> 1721-GMB-28a-X / 17-GMB-08j-Y						
<b>3. Date of Decision Letter:</b> 16 May 2017						
<b>4. Date of the Partnership Framework Agreement:</b> 3 <sup>rd</sup> February 2014						
<b>5. Programme title:</b> New Vaccine Support (NVS), Meningitis A Preventive Routine						
<b>6. Vaccine type:</b> Meningitis A						
<b>7. Requested product presentation and formulation of vaccine:</b> Meningococcal type A, 10 dose(s) per vial, LYOPHILISED						
<b>8. Programme duration<sup>1</sup>:</b> 2017 - 2021						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)						
	2017	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	US\$15,500	US\$60,000	US\$53,000	US\$53,500	US\$55,000	US\$237,000
<b>10. Vaccine introduction grant (in US\$):</b> 100,000. Payable up to six months before vaccine introduction.						
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>3</sup>						
Type of supplies to be purchased with Gavi funds in each year			2017	2018		
Number of Meningitis A vaccines doses			30,000	117,000		
Annual Amounts (US\$)			US\$15,500	US\$60,000		
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
<b>13. Self-procurement:</b> Not applicable						

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**14. Co-financing obligations:** Reference code: 1721-GMB-28a-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	20,000	76,500	67,000	68,000
Value of vaccine doses (US\$)	US\$9,625	US\$37,248	US\$32,724	US\$33,301
Total co-financing payments (US\$) (including freight)	US\$10,000	US\$39,000	US\$34,000	US\$35,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

16 May 2017